生产企业：REGENXBIO Inc.
RGX-314 (surabgene lomparvovec; ABBV-RGX-314) is an investigational AAV gene therapy developed by REGENXBIO in collaboration with AbbVie, in late-stage development as a one-time treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
RGX-314 (surabgene lomparvovec; ABBV-RGX-314) is an investigational AAV gene therapy developed by REGENXBIO in collaboration with AbbVie, in late-stage development as a one-time treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
For the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
